1980
DOI: 10.1038/clpt.1980.98
|View full text |Cite
|
Sign up to set email alerts
|

Plasma levels and urinary excretion of vidarabine after repeated dosing

Abstract: Vidarabine (Vira-A) was given intravenously for 5 days to 5 immunosuppressed patients with herpes zoster. The daily dose, 10 mg/kg, was given by slow infusion over 12 hr. Blood samples were taken at 0, 1, 2, 4, 8, and 12 hr on days 1, 3, and 5. Twenty-four-hour urine specimens were collected before treatment and on days 1, 3, and 5. Blood and urine specimens were assayed for vidarabine and its principal metabolite, hypoxanthine arabinoside (ara-Hx), by high pressure liquid chromatography. The results showed th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
10
0

Year Published

1985
1985
1998
1998

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(10 citation statements)
references
References 2 publications
0
10
0
Order By: Relevance
“…In fact while many studies were unable to detect vidarabine after a 12h infusion, ara-Hx concentrations ranged from 3 to 6 mg/L after a 12h infusion of vidarabine 5 to 15 mg/kg/day (Whitley et al 1980a). Urinary recovery of ara-Hx after continuous infusion of vidarabine range from 40 to 50% of the administered dose (Buchanan et al 1980;LePage et al 1973;Preiksaitis et al 1981;Shope et al 1983). Therefore, renal excretion is the predominant elimination pathway for ara-Hx.…”
Section: Vidarabinementioning
confidence: 95%
“…In fact while many studies were unable to detect vidarabine after a 12h infusion, ara-Hx concentrations ranged from 3 to 6 mg/L after a 12h infusion of vidarabine 5 to 15 mg/kg/day (Whitley et al 1980a). Urinary recovery of ara-Hx after continuous infusion of vidarabine range from 40 to 50% of the administered dose (Buchanan et al 1980;LePage et al 1973;Preiksaitis et al 1981;Shope et al 1983). Therefore, renal excretion is the predominant elimination pathway for ara-Hx.…”
Section: Vidarabinementioning
confidence: 95%
“…The serum half-life of arabinoside hypoxanthine is about 5 h. Most of the drug is excreted in the urine as arabinoside hypoxanthine, which accounted for 40 to 50% of the dose; vidarabine appears in the urine unchanged for 2% of the dose [14]. Arabinoside hypoxanthine is much less active than vidarabine itself, but synergism occurs between arabinoside hypoxanthine and vidarabine [9].…”
Section: Vidarabinementioning
confidence: 99%
“…DISCUSSION The HPLC methods described in this report permit the detection of Ara-AMP and Ara-A in plasma and urine at levels far below those which can be quantitated by previously published methods (2-4, 14, 16). The sensitivity of the method for Ara-H is comparable to that of other HPLC methods (2,4,14,16), but we have developed an additional means for detecting and correcting for an interfering substance sporadically found in urine samples. 42:1140, 1983) described human plasma AMa-A concentrations at steady-state conditions during constant intravenous infusions of Ara-A of 0.016 to 0.025 p.g/ml and used the methodology given in detail in the present report.…”
mentioning
confidence: 85%
“…Previous studies of the pharmacokinetics of these drugs have indicated that Ara-AMP is rapidly converted to Ara-A and that the latter, whether derived from Ara-AMP or infused directly intravenously, is rapidly converted to arabinosylhypoxanthine (Ara-H) (1,4,14,21). The methods used, however, for determining Ara-AMP and Ara-A concentrations in plasma and urine in these previous studies were too insensitive to permit detailed pharmacokinetic studies except for brief periods after rapid intravenous Ara-AMP dosing (14).…”
mentioning
confidence: 99%
See 1 more Smart Citation